Regentis Biomaterials Ltd. (RGNT)

Regentis Biomaterials will go public soon, but the exact IPO date is still unknown.

IPO Price Range

$10.00 - $12.00

Shares Offered

909,090

Deal Size

$10.00M

Regentis Biomaterials Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	-	1.13	0.44
Research & Development	-	0.81	0.97
Operating Expenses	-	1.93	1.41
Operating Income	1.15	-1.93	-1.41
Interest Expense / Income	2.18	2.2	0.04
Pretax Income	6.36	-4.13	-1.45
Net Income	6.36	-4.13	-1.45
Free Cash Flow	-0.46	-1.22	-1.5
EBITDA	8.54	-1.93	-1.41
EBIT	8.54	-1.93	-1.41

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).